瑞舒伐他汀治疗急性冠脉综合征合并心律失常的疗效及其对血清炎性因子的影响

摘要

Objective To analyze the clinical efficacy of rosuvastatin in the treatment of patients with acute coronary syndrome complicated with arrhythmia and its influence on serum inflammatory factors.Methods A total of 96 patients with acute coronary syndromes complicated with arrhythmia were selected and randomly divided into observation group and control group,48 cases in each group.The patients in the control group were treated with lovastatin,while the patients in the observation group were treated with rosuvastatin.The levels of inflammatory factors,apoptosis and drug-induced adverse reactions were compared between the two groups.Results After treatment,the levels of IL-18,TNF-α,hs-CRP and C-myc,Bcl-2 protein improved significantly in both groups,and these indexes in observation group were significantly better than control group (P ＜ 0.05).There was no significant difference in incidence rate of adverse reactions between the two groups (P ＞0.05).Conclusion Rosuvastatin is effective and safe in the treatment of patients with acute coronary syndrome complicated with arrhythmia.%目的 分析瑞舒伐他汀药物治疗急性冠脉综合征合并心律失常的临床疗效及其对血清炎性因子的影响.方法 选取急性冠脉综合征合并心律失常患者96例,随机分为观察组和对照组各48例.对照组患者给予洛伐他汀治疗,观察组患者给予瑞舒伐他汀进行治疗,比较2组患者的血清炎性因子水平、细胞凋亡指标及药物不良反应情况.结果 治疗后,2组患者的白介素-18(IL-18)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平及C-myc、Bcl-2蛋白指标水平均显著改善,且观察组改善显著优于对照组(P＜0.05).2组不良反应的发生率比较,差异无统计学意义(P＞0.05).结论 瑞舒伐他汀药物治疗急性冠脉综合征合并心律失常患者安全有效.